A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Abroad (travel likely)RecruitingPHASE2
Conditions
Amyloidosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
GSK Investigational Site, Rochester, Minnesota, United States
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Shaji Kumar)GSK Investigational Site, Westmead, New South Wales, Australia
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Fiona Kwok)GSK Investigational Site, Woolloongabba, Queensland, Australia
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Nirija Anderson)GSK Investigational Site, Box Hill, Victoria, Australia
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Brendan Wisniowski)GSK Investigational Site, Frankston, Victoria, Australia
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Patricia Walker)